Dongsik Park

USPTO Granted Patents = 6 (Patent Applications = 3)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 9.3

ph-index = 1

Company Filing History:

Lead Discovery Center Gmbh

patents

2 out of 10

Institut Pasteur Korea

patents

where one patent can have more than one assignee

Years Active: 2017-2024

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12162858 - Quinoline derivatives as inhibitors of AXL/MER RTK and CSF1R (2024-12-10),

2. 11945822 - Pyrazolo-triazine and/or pyrazolo-pxrimidine derivatives as selective inhibitor of cyclin dependent kinase (2024-04-02),

3. 11858937 - Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors (2024-01-02),

4. 11447486 - 2-amino-benzimidazole derivatives and their use as 5-lipoxygenase and/or prostaglandin E synthase inhibitors (2022-09-20),

5. 10934274 - Quinoline derivatives as TAM RTK inhibitors (2021-03-02),

6. 9809602 - Compounds for treating viral infections (2017-11-07),

Title: The Innovative Mind of Dongsik Park

Introduction

Dongsik Park is a notable inventor based in Gyeonggi-do, South Korea, known for his significant contributions to the field of pharmaceuticals. With a total of six patents to his name, he has made impactful advancements in treatments for various diseases, paving the way for innovative therapeutic options.

Latest Patents

Among Dongsik Park's latest patents are groundbreaking inventions focused on new chemical compounds. One such patent details "Quinoline derivatives as inhibitors of AXL/MER RTK and CSF1R." This invention revolves around quinoline derivatives that serve as inhibitors for Axl/Mer RTK and CSF1R, which are essential targets in the context of hyperproliferative disorders, particularly cancers that exhibit immune suppression in their tumor microenvironments. These compounds also show potential in treating inflammatory and neurodegenerative diseases.

Another notable patent is for "Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitors of cyclin-dependent kinase." This invention presents derivatives that are useful as active pharmaceutical agents targeting cell proliferative, inflammatory, immunological, cardiovascular, and infectious diseases. The patent also includes pharmaceutical compositions containing these derivatives, further exemplifying the innovative applications of his research.

Career Highlights

Dongsik Park has developed a robust career with notable engagements in significant organizations. He has contributed his expertise at Qurient Co., Ltd., a company focused on developing innovative therapeutics, and at Lead Discovery Center GmbH, where he has worked on pivotal drug discovery projects. His work emphasizes creating impactful solutions in medicine through innovative research.

Collaborations

Throughout his career, Dongsik Park has collaborated with esteemed colleagues such as Kiyean Nam and Jaeseung Kim. These partnerships highlight the importance of teamwork in driving innovation and research, ultimately contributing to advancements in the pharmaceutical field.

Conclusion

Dongsik Park's ongoing dedication to research and development has led to significant advancements in pharmaceuticals. With his six patents, he continues to inspire the scientific community and contribute to the betterment of healthcare solutions. His work not only addresses critical health issues but also sets a precedent for future innovations in medical treatments.

This text is generated by artificial intelligence and may not be accurate.